Answers are grounded in this paper and cite their sources.
Real-world cohort assesses the efficacy and safety of concizumab in patients with hemophilia B and inhibitors, highlighting personalized care needs.
In this nationwide real-world cohort, concizumab prophylaxis was effective, well tolerated, and manageable in routine practice, including during surgical procedures. These data support its use as a valuable prophylactic option in carefully selected patients with hemophilia B and inhibitors, while underscoring the importance of individualized monitoring and thrombotic risk assessment.
No takes yet. Share an insight, caveat, or question.
Caroline et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: